197 completed. 197 Phase 3, 11 Phase 2.
By phase and status
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Trials (filtered) newest first · largest first
All 197 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 3 | Completed | 514 | 2023-04-14 | 2026-02-18 |
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | 1 | 2022-02-16 | 2025-05-23 |
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | 154 | 2021-07-12 | 2026-08-10 |
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma
Positron Emission Tomography using 18F-FCH, Positron Emission Tomography using 18F-FDG - Myeloma Multiple | Phase 3 | Completed | 20 | 2019-11-12 | 2026-05-12 |
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Daratumumab SC in combination with Lenalidomide, Lenalidomide PO (25mg), Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression - Multiple Myeloma | Phase 3 | Completed | 294 | 2019-10-17 | 2026-09-23 |
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Carfilzomib, Lenalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | 454 | 2019-05-08 | 2024-08-13 |
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | 200 | 2019-04-26 | 2026-06-23 |
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
bb2121, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 3 | Completed | 386 | 2019-04-16 | 2026-06-22 |
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 3 | Completed | 289 | 2019-03-27 | 2024-07-03 |
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Ixazomib - Multiple Myeloma | Phase 3 | Completed | 37 | 2019-01-24 | 2025-03-21 |
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | 395 | 2018-11-06 | 2026-06-02 |
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Daratumumab, Velcade, Dexamethasone - Multiple Myeloma | Phase 3 | Completed | 213 | 2017-11-30 | 2024-05-29 |
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Velcade, Melphalan, Prednisone - Multiple Myeloma | Phase 3 | Completed | 220 | 2017-11-23 | 2024-04-25 |
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Daratumumab, JNJ-63723283 - Multiple Myeloma | Phase 2 / Phase 3 | Completed | 10 | 2017-11-16 | 2025-02-04 |
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Dara SC, Dara IV - Multiple Myeloma | Phase 3 | Completed | 522 | 2017-10-27 | 2025-04-29 |
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
isatuximab SAR650984, carfilzomib, dexamethasone - Plasma Cell Myeloma | Phase 3 | Completed | 302 | 2017-10-25 | 2026-02-09 |
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
Hematopoietic stem cells transplantation - Acute Leukemia, Non Hodgkin Lymphoma | Phase 3 | Completed | 9 | 2017-09-19 | 2026-10-01 |
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
Daratumumab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Completed | 304 | 2017-06-14 | 2025-12-19 |
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Dexamethasone, Daratumumab, Carfilzomib - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 3 | Completed | 466 | 2017-06-13 | 2025-05-09 |
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Selinexor, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 3 | Completed | 402 | 2017-05-24 | 2024-08-21 |
Showing 20 of 197. Sign in to see all of them.
Narrower conditions
Neoplasms, Plasma Cell (47) · Hodgkin Disease (28) · Lymphoma, Non-Hodgkin (27) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Lymphoma (24) · Lymphoma, Large B-Cell, Diffuse (23) · Lymphoma, Mantle-Cell (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Recurrence (23) · Leukemia, Myeloid, Acute (21) · Lymphoma, Follicular (21) · Lymphoma, Large-Cell, Immunoblastic (21) · Lymphoma, B-Cell, Marginal Zone (20) · Burkitt Lymphoma (19)
Broader conditions
Hemic and Lymphatic Diseases (197) · Cardiovascular Diseases (196) · Hemorrhagic Disorders (196) · Hemostatic Disorders (196) · Immune System Diseases (196) · Neoplasms by Histologic Type (196) · Vascular Diseases (196) · Blood Protein Disorders (195) · Immunoproliferative Disorders (195) · Paraproteinemias (194) · Hematologic Diseases (193) · Lymphoproliferative Disorders (188) · Neoplasms (178) · Neoplasms, Plasma Cell (150) · Pathological Conditions, Signs and Symptoms (52)
Interventions
Dexamethasone (77) · Bortezomib (46) · Lenalidomide (41) · Thalidomide (33) · Melphalan (26) · Cyclophosphamide (14) · Calcium Dobesilate (13) · Prednisone (13) · daratumumab (12) · carfilzomib (10) · Doxorubicin (8) · Peripheral Blood Stem Cell Transplantation (8) · ixazomib (8) · pomalidomide (8) · Filgrastim (7)
Sponsors
Celgene (13) · Janssen Research & Development, LLC (12) · Amgen (11) · Fred Hutchinson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (7) · University of Arkansas (7) · Alliance for Clinical Trials in Oncology (6) · PETHEMA Foundation (6) · Bristol-Myers Squibb (5) · Fondazione EMN Italy Onlus (5) · Celgene Corporation (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · National Cancer Institute (NCI) (4) · Janssen-Cilag G.m.b.H (3) · M.D. Anderson Cancer Center (3)
Countries
United States (103) · Germany (52) · France (51) · Spain (48) · Canada (43) · Italy (42) · United Kingdom (41) · Belgium (39) · Czechia (32) · Greece (32) · Australia (31) · Sweden (30) · Austria (29) · Poland (29) · Israel (26)
Top investigators
Robert Knight, MD (6) · Mario Boccadoro, MD (4) · Mary Horowitz, MD (3) · Amine Bensmaine, MD (2) · Bart Barlogie, M.D., Ph.D. (2) · Brenda Sandmaier (2) · Chaim Shustik, MD (2) · David J. Straus, MD (2)
Results publications
PMID 31221778, PMID 34289038, PMID 22689675, PMID 38023148, PMID 39229471, PMID 18799726, PMID 19901114, PMID 21160068, PMID 21228328, PMID 21273172, PMID 21791470, PMID 23897961, PMID 24117042, PMID 25261096, PMID 26771810, PMID 27002117, PMID 27738789, PMID 28293022, PMID 29675792, PMID 30561775, PMID 31221782, PMID 31231828, PMID 31248973, PMID 32499241, PMID 33513030, PMID 34269818, PMID 34587246, PMID 35876974, PMID 36108425, PMID 36130300, PMID 38031761, PMID 38048391, PMID 38048552, PMID 39293025, PMID 42085642, PMID 15459300, PMID 15968290, PMID 16224404, PMID 16365178, PMID 16404741, PMID 16419071, PMID 16432076, PMID 16505427, PMID 16525139, PMID 16530576, PMID 16710026, PMID 17233817, PMID 17397698, PMID 17679727, PMID 17875806
NIH funding
2014 (7), 2005 (6), 2008 (4), 2018 (4), 2017 (3), P30CA015083 (3), 2004 (2), 2009 (2), 2015 (2), 2016 (2), P30CA015704 (2), P30CA068485 (2), U01HL069294 (2), U10CA021115 (2), U10CA032102 (2)